Renowned Chinese investment companies will gather in San Francisco to find their favorite projects and partners.
If you are looking for fundraising and partnership, don’t be hesitate to join us and present your company(Pitch & Match) at China Focus@San Francisco!
Only through Pitch & Match, we provide our investors and presenting companies the opportunity to know each other before event day, get engaged through the presentation, Q&A and arrange immediate follow-up meetings.
Founded in Shenzhen in 2001, GTJA INVESTMENT GROUP (GIG) is dedicated to investment in healthcare industry with a focus on strategic equity investment. GIG is involved in the entire investment stages which include M&A, PE, VC, and angel investment. Currently, GIG has the largest and most professional team for healthcare investment in China. We have established an eco platform in healthcare investment sectors and is devoted to becoming a healthcare investment institution with global influence.
GIG has an AUM of ￥20 B and has raised 24 funds dedicating to the healthcare industry. GIG has invested in more than 130 companies, 60 of which are in the healthcare industry. Ten of our portfolio companies have gone through IPO, and notably, GIG also acts as the holding company of Boya Bio-Pharmaceutical (SZ.300294)
Overseas Partner, Head of International Business Development
KPCB China‘s investment advisory team operates independently and with flexibility focusing on Digital, Green Tech, and Life science opportunities. The investment advisory team is focused on identifying and promoting innovation and supporting entrepreneurs and portfolio companies for long-term, sustained growth and success. KPCB’s investment teams collaborate closely taking full advantage of each other’s deep expertise, rich experience, and unparalleled global network, providing China’s entrepreneurs with a global resource platform.
Qiming Venture Partners was founded in China in 2006 and has over $4 billion in total assets under management. In January 2017, Qiming launched Qiming USA, focused on early-stage healthcare opportunities in the United States and Europe. Situated in the major life science hubs of Cambridge, San Francisco Bay Area and Seattle, we invest in highly disruptive platforms and products addressing significant unmet medical needs, driven by passionate and committed teams with the depth and experience to succeed.
KAITAI CAPITAL, founded in 2009, is a professional investment management organization that mainly engaged in innovative investment, industrial investment, and wealth management business. Fields of investment include biopharma, healthcare services, agriculture tech, consumer business, digital technology and etc. Currently, the asset under management of KAITAI CAPITAL has reached 50 billion RMB (USD$7.2B).
CDIB Capital International (“CDIB Capital”) invests in compelling growth-oriented companies seeking to capitalize on cross-market opportunities in the Asia-Pacific region. Their industry expertise, extensive local knowledge, and regional footprint enable them to collaborate with partners to boost enterprise value and gain cross-fertilization between China and closely linked economies.
Executive VP & Managing Director- Healthcare Investments
Date: Nov 10, 2019
Location: Grand Elysée Hamburg
Date: Jan 12, 2020